Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BioCity Approved to Start US Trial of Bispecific Antibody for Solid Tumors

publication date: Aug 9, 2023

BioCity Biopharma of WuXi, China was cleared to start a US Phase I study of BC3448, a CD3/EGFR bispecific antibody that will enroll patients with advanced solid tumors. The candidate recruits T cells to tumors cells with high EGFR expression, killing the tumor cells. To reduce the possibility of cytokine release syndrome, BC3448 is designed to have differential binding affinities for EGFR and CD3, with a stronger binding affinity for EGFR than CD3. The candidate is being developed for solid tumors with high EGFR expression, including NSCLC, HNSCC, mCRC and ESC. BayCity has already started a similar trial of BC3448 in China. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital